| Literature DB >> 32735092 |
Sarah Schmitt1, Roger Stephan1, Ella Huebschke1, Daniel Schaefle1, Axel Merz1, Sophia Johler2.
Abstract
BACKGROUND: Methicillin-resistant Staphylococcus aureus (MRSA) is a leading cause of severe infections in humans and animals worldwide. Studies elucidating the population structure, staphylococcal cassette chromosome mec types, resistance phenotypes, and virulence gene profiles of animal-associated MRSA are needed to understand spread and transmission.Entities:
Keywords: MRSA; MRSP
Mesh:
Year: 2020 PMID: 32735092 PMCID: PMC7402938 DOI: 10.4142/jvs.2020.21.e54
Source DB: PubMed Journal: J Vet Sci ISSN: 1229-845X Impact factor: 1.672
Overview of resistance phenotypes and MIC50/MIC90 values determined for the 28 methicillin-resistant Staphylococcus aureus isolates tested in this study
| Antimicrobial agent | Susceptible (%) | Intermediate (%) | Resistant (%) | MIC50 | MIC90 | Clinical breakpoints applied* |
|---|---|---|---|---|---|---|
| Penicillin | 0 | - | 100 | ≥ 0.5 | ≥ 0.5 | Human clinical breakpoint |
| Ampicillin/sulbactam (2/1)† | - | - | - | 8 | ≥ 32 | - |
| Oxacillin | 0 | - | 100 | ≥ 4 | ≥ 4 | Human clinical breakpoint |
| Imipenem | - | - | - | ≤ 1 | ≤ 1 | - |
| Vancomycin | 100 | 0 | 0 | ≤ 0.5 | 1 | Human clinical breakpoint |
| Erythromycin | 96 | 0 | 4 | ≤ 0.25 | 0.5 | Human clinical breakpoint |
| Fusidic acid | - | - | - | ≤ 0.5 | ≤ 0.5 | - |
| Mupirocin | - | - | - | ≤ 2 | ≤ 2 | - |
| Rifampicin | 100 | 0 | 0 | ≤ 0.5 | ≤ 0.5 | Human clinical breakpoint |
| Kanamycin | - | - | - | ≥ 64 | ≥ 64 | - |
| Gentamicin | 25 | 14 | 61 | ≥ 16 | ≥ 16 | Human clinical breakpoint |
| Enrofloxacin | 68 | 0 | 32 | ≤ 0.5 | ≥ 4 | Veterinary clinical breakpoint (dogs) |
| Marbofloxacin | 68 | 0 | 32 | ≤ 0.5 | ≥ 4 | Veterinary clinical breakpoint (dogs) |
| Tetracycline | 0 | 0 | 100 | ≥ 16 | ≥ 16 | Human clinical breakpoint |
| Nitrofurantoin | 96 | 0 | 4 | ≤ 16 | 32 | Human clinical breakpoint |
| Chloramphenicol | 100 | 0 | 0 | ≤ 4 | 8 | Human clinical breakpoint |
| Clindamycin | 96 | 0 | 4 | ≤ 0.25 | ≤ 0.25 | Veterinary clinical breakpoint (dogs) |
| Trimethoprim/sulfamethoxazole (1/19)† | 25 | - | 75 | ≥ 16 | ≥ 16 | Human clinical breakpoint |
This overview of resistance phenotypes and MIC50/MIC90 values is based on human or veterinary clinical breakpoints. For the MIC distribution, see Supplementary Table 2.
MIC, minimum inhibitory concentration.
*Due to a lack of available veterinary clinical breakpoints for all host species, classification as susceptible/intermediate/resistant is based on human clinical breakpoints or veterinary clinical breakpoints determined for dogs [11]; †MIC values given represent the MIC values for ampicillin and trimethoprim, respectively.
Overview of typing and characterization results
| CC | Host | SCC | Resistance genes* | Resistance phenotype† | Virulence genes* | |
|---|---|---|---|---|---|---|
| CC398 (n = 24) | t011 (n = 23) | Horse (n = 15) | IV | n = 6: PEN, OXA, FOX, TET, SXT, GEN | - | |
| n = 3: PEN, OXA, FOX, TET, SXT, (GEN) | - | |||||
| n = 3: PEN, OXA, FOX, TET, SXT, GEN, EFX, MAR | - | |||||
| n = 1: PEN, OXA, FOX, TET, SXT, GEN, EFX, MAR, NIT | - | |||||
| n = 1: PEN, OXA, FOX, TET, SXT, GEN, EFX, MAR | - | |||||
| n = 1: PEN, OXA, TET, SXT | - | |||||
| Pig (n = 5) | V (n = 3) | PEN, OXA, FOX, TET | - | |||
| IV (n = 2) | PEN, OXA, FOX, TET | - | ||||
| PEN, OXA, FOX, TET, SXT, (GEN) | - | |||||
| Cattle (n = 1) | IV | PEN, OXA, FOX, TET, SXT, GEN | - | |||
| Sheep (n = 1) | IV | PEN, OXA, FOX, TET, SXT, GEN, EFX, MAR | - | |||
| Dog (n = 1) | IV | PEN, OXA, FOX, TET, SXT, GEN, EFX, MAR | - | |||
| t034 (n = 1) | Cattle | V | PEN, OXA, FOX, TET | - | ||
| CC8 (n = 3) | t009 (n = 2) | Horse | Atypical | PEN, OXA, FOX, TET, SXT, GEN | ||
| PEN, OXA, TET, SXT, GEN, EFX, MAR | ||||||
| t008 (n = 1) | Horse | IV | PEN, OXA, FOX, TET, GEN, EFX, MAR | |||
| CC1 (n =1) | t127 (n = 1) | Dog | IV | PEN, OXA, FOX, TET |
CC, spa type, and SCCmec type were determined for the MRSA isolates (n = 28) included in this study. The table also provides information on resistance phenotypes, and it lists resistance and virulence genes detected by DNA microarray.
CC, clonal complex; SCCmec, staphylococcal cassette chromosome mec; MRSA, methicillin-resistant Staphylococcus aureus; PEN, penicillin; OXA, oxacillin; FOX, cefoxitin; TET, tetracycline; SXT, trimethoprim/sulfamethoxazole; GEN, gentamicin; ERY, erythromycin; MAR, marbofloxacin; EFX, enrofloxacin; CLI, clindamycin; VAN, vancomycin; NIT, nitrofurantoin; CHL, chloramphenicol; RIF, rifampicin.
*The presence of selected resistance and virulence genes determined by DNA microarray is stated. For a full report see Supplementary Table 1. None of the isolates harbored mecC, pvl encoding Panton-Valentine leukocidin, or genes encoding exfoliative or toxic shock syndrome toxins; †Due to lack of available clinical breakpoints for all host species, classification as intermediate (antimicrobial indicated in brackets) or resistant is based on human clinical breakpoints or veterinary clinical breakpoints determined for dogs, which may not apply to the host species from which the MRSA was isolated.
Fig. 1SplitsTree depicting the similarity between the virulence and resistance gene profiles of the investigated strain collection, comprising 28 MRSA strains (numbers only) and 3 MRSP strains. Host species are indicated by color codes: 18 strains originated from horses (green), 5 from dogs (yellow), 5 from pigs, 2 from cows (pink), and one from a sheep (orange).
MRSA, methicillin-resistant Staphylococcus aureus; MRSP, methicillin-resistant Staphylococcus pseudintermedius; CC, clonal complex.